**Exome sequencing identifies a disease variant of the mitochondrial ATP-Mg/Pi carrier SLC25A25 in two families with kidney stones**

**Running title: *SLC25A25* variant in familial kidney stone disease**

M. Reza Jabalameli1†‡, Fiona M. Fitzpatrick2†, Roberto Colombo3, Sarah A. Howles4, Gary Leggatt1,5, Valerie Walker6, Akira Wiberg7, Edmund R.S. Kunji2, Sarah Ennis1

†These authors contributed equally to this manuscript:M Reza Jabalameli, Fiona Fitzpatrick

**Affiliations:**

1 Department of Human Genetics and Genomic Medicine, University of Southampton, Duthie Building, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK

2 Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Keith Peters building, Hills road, Cambridge, CB2 0XY, United Kingdom

3 Faculty of Medicine ‘Agostino Gemelli’, Catholic University of the Sacred Heart, Rome, Italy & Center for the Study of Rare Inherited Diseases, Niguarda Ca´ Granda Metropolitan Hospital, Milan, Italy

4 Nuffield Department of Surgical Sciences, University of Oxford, Headington, Oxford, OX39DU, United Kingdom

5 Wessex Kidney Centre, Queen Alexandra Hospital, Portsmouth, PO6 3LY, United Kingdom

6 Department of Clinical Biochemistry, University Hospital Southampton, Southampton, Tremona Road, Southampton, SO16 6YD, United Kingdom

7 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Headington, Oxford, OX37LD, United Kingdom

‡ Current address, Department of Genetics, Albert Einstein College of Medicine, Bronx New York 10461; USA

**Corresponding Author:** Professor Sarah Ennis email: [se@soton.ac.uk](mailto:se@soton.ac.uk)

Address enquiries about the modelling/ mitochondrial data directly to Professor Edmund Kunji: [ek@mrc-mbu.cam.ac.uk](mailto:ek@mrc-mbu.cam.ac.uk)

**Financial support:** The Southampton studies were funded by Southampton Hospital Charity Registered Charity 1051543; The structural modelling and functional analyses were supported by program grant MC\_UU\_00015/1 from the Medical Research Council UK. The UK Biobank Study ID 885 was supported by a grant from Kidney Research UK (RP\_030\_20180306). SH and AW are Academic NIHR Clinical Lecturers.

**ABSTRACT**

**Background**

Calcium kidney stones are common and recurrences are often not preventable by available empiric remedies. Their etiology is multifactorial and polygenic, and an increasing number of genes are implicated. Their identification will enable improved management.

**Methods**

DNA from three stone-formers in a Southampton family (UK) and two from an Italian family were analyzed independently by whole exome sequencing and selected variants were genotyped across all available members of both pedigrees. A disease variant of *SLC25A25* (OMIM 608745), encoding the mitochondrial ATP-Mg/Pi carrier 3 (APC3) was identified, and analyzed structurally and functionally with respect to its calcium-regulated transport activity.

**Results**

All five patients had a heterozygous dominant *SLC25A25* variant (rs140777921; GRCh37.p13: chr 9 130868670 G>C; p.Gln349His; Reference Sequence NM\_001006641.3). Non-stone formers also carried the variant indicating incomplete penetrance. Modelling suggests that the variant lacks a conserved polar interaction, which may cause structural instability. Calcium-regulated ATP transport was reduced to approximately 20% of the wild type, showing a large reduction in function.

**Conclusion**

The transporter is important in regulating mitochondrial ATP production. This rare variant may increase urine lithogenicity throughimpaired provision of ATP for solute transport processes in the kidney, and/or for purinergic signaling. Variants found in other genes may compound this abnormality.

**Key words**

Calcium kidney stones; calcium signaling; purinergic signaling; mitochondrial adenine nucleotide metastasis; mitochondrial transporter

1 **INTRODUCTION**

Renal stones are aggregates of inorganic and/or organic crystals formed within the kidneys. They are common world-wide with recent estimated life-time prevalence in men of around 10%. They often recur and this may impact significantly on the lives of stone formers. More than 75% are calcium oxalate stones, often mixed with calcium phosphate. Most of these are idiopathic. Many factors contribute to their formation, notably an increased concentration of minerals due to low fluid intake or dietary excesses, hormonal imbalance and decreased protection by endogenous inhibitory agents in urine (Coe, Evan & Worcester, 2005; Moe, 2006; Prochaska, Taylor, & Curhan, 2016; Walker, Stansbridge & Griffin, 2013). These factors are variable and change throughout life. However, there is also an underlying genetic component, with heritability estimated at about 50%. Around 20% of stone formers have a positive family history of stones compared with 6% among non-stone formers (Coe et al., 2005; Curhan, Willett, Rimm & Stampfer, 1996; Goldfarb, Avery, Beara-Lasic, Duncan & Goldberg, 2019; Gambaro et al., 2016; Walker, 2013). Well-established monogenic causes of stone disease are being recognised increasingly in individuals referred to specialist clinics because of significant stone problems without a previous genetic diagnosis (Braun, Lawson, Daga, et al., 2016; Daga, Majmundar, Braun, et al., 2018; Gambaro et al., 2016; Halbritter, Baum, Hynes et al., 2016, Sayer, 2017; Vezzoli,Terranegra, Arcidiacono & Soldati, 2011). However, in the majority of stone formers, genetic susceptibility is polygenic with co-inheritance of multiple small effect gene variants. GWAS studies have identified common polymorphisms (MAF>1%) in 31 genes associated with stone formation, most with modest effects (OR<1.5) (Howles & Thakker, 2020; Moe, 2006; Palsson, Indridason, Edvardsson & Oddsson, 2019). In other complex polygenic disorders such as diabetes mellitus, common polymorphisms do not fully account for genetic susceptibility. Rare/low frequency variants are likely to contribute to the missing genetic component (Pang et al., 2021). Current interventions to prevent stone recurrence are still largely empiric and often ineffective (Gambaro et al., 2016). Progress with targeted treatment and prevention demands a better understanding of the underlying genetic factors.

Two decades ago, we undertook a small study in Southampton to look for variants in genes relevant to stones in fourteen kindreds in which at least three first degree relatives had had calcium stones (Walker & Griffin, 2015). Family members had biochemical investigation for stone risk factors. Mouth wash DNA was analyzed using microsatellites to investigate the segregation of four genes with stone formation. (*Vitamin D Receptor (VDR;* OMIM 601769*), Calcium Sensing Receptor (CASR;* OMIM 601199*), Thiazide-sensitive Sodium Chloride Transporter (SLC12A3;* OMIM 600968*)* and *Sodium Phosphate Transporter 2a (SLC34A1* OMIM 182309). The results were negative. Many other studies have looked for polymorphisms in candidate genes known to influence urine composition which might increase the risk for stones. No common clear leaders have emerged (Palsson, 2019; Sayer, 2017; Vezzoli, 2011; Walker, 2019).

With whole exome sequencing (WES) and genome-wide association studies (GWAS), there is the potential to extend the search to the wide range of intracellular proteins that underpin urine production (Howles et al., 2019; Palsson, 2019; Tanikawa, 2019; Walker, 2019). In order to look further for gene variants responsible for increasing risk for kidney stones in these families we have now analyzed blood stored from the study by WES.

A heterozygous dominant rare variant in the gene *SLC25A25* (*Solute* *Carrier Family 25 member 25)* was identified in stone formers in one Southampton kindred. This encodes the mitochondrial ATP-Mg/Pi carrier 3, APC3 (aliases SCaMC2 [Small Calcium-Binding Mitochondrial Carrier 2] and SLC25A25 [Solute Carrier Family 25 member 25] (del Arco & Satrústegui, 2004; Fiermonte et al., 2004). The same variant was identified independently in an Italian pedigree, and segregated well with stone formation.

**2 PATIENTS AND METHODS**

**2.1 Ethical Compliance**

All the studies were conducted according to the Helsinki Declaration with ethical committee approval. Written and informed consent was obtained from all participants.

The first Southampton Study was approved by the Southampton and South West Hampshire Research Ethics Committee (1997; Ref 322/970) and the second by the East of England- Cambridge Central Research Ethics Committee (2016; Ref 16/EE/0293).

The Italian study was performed according to the Italian National Bioethics Committee.

UK Biobank has approval from the North West Multi-Centre Research Ethics Committee (11/NW/0382). The reported study (Epidemiology of Kidney Stone Disease) has UK Biobank Study ID 885.

**2.2 The Families**

The Southampton family was initially recruited to our study in 1998. Seven individuals spanning three generations were stone formers (3 deceased) (Figure 1a). The propositus (II-1), a 79-year old patient of the Southampton stone clinic had her first stone aged 44 years and another, containing calcium, oxalate and phosphate, at 78 years. Her mother (I-4) had a nephrectomy for stones aged 39 years. Four other family members had renal stones aged 18 to 64 years. A further male patient (II-6) is not known to have had kidney stones but formed 2cm bladder calculus on an indwelling catheter for Parkinson’s disease. Twelve adults ≥ 18 years of age provided blood and urine for biochemical investigations and blood and mouth wash samples for DNA analysis. None of the family had primary hyperparathyroidism or, with the exception of patient II-6, another underlying medical disorder associated with urinary tract stones. At the time of consenting to the follow-up study in 2016, the participants were asked to complete a short questionnaire (Document S1) asking whether they had formed more stones, had chronic illnesses, repeat medications and whether any of their children or grand-children had had kidney stones. In addition, their records held on the hospital computer system were reviewed for relevant clinical and biochemical data. DNA extracted from blood stored at -20 °C from stone formers II-1, III-5, and III-7 was analyzed by WES. Segregation of selected rare variants with stones was investigated by genotyping DNA from all twelve participants.

**Figure 1** **Pedigrees of the two families showing apparent autosomal dominant inheritance of stones.** (a) UK family: DNA from individuals II-1, III-5 and III-7 were analyzed by WES; segregation of the variant in the family was by Kaspar genotyping. (b) Italian kindred: The left and the right branch of the pedigree trace their ancestry to a common family founder, indicated by the dashed lines. DNA from individuals II-2, III-3 were analyzed by WES and the variant confirmed by Sanger sequencing. Segregation of the variant was by restriction analysis; Solid symbols: stone formers; Δ-miscarriages

The propositus in the family from Southern Italy sought counselling aged 51 years because of recurrent stones, having had three removed from 32 years of age. He was physically very active and otherwise healthy, with no history of hypertension or diabetes and was not taking medications. His mother (I-3 in Figure 1b), maternal uncle (I-4, 76 years), and youngest son (III-3, 21 years) had one or more kidney stones. From family members and contacts with general practitioners another five related subjects were identified spanning three generations, four still alive in 2016 (I-7, II-5, II-7 and III-8) and one deceased (I-9). Through consultation of parish and civil registers of births and marriages the family was found to have two branches with the common ancestors born in 1888 and 1891. All participants provided a blood sample or buccal swab for genotyping. Samples from II-2 and III-3 were analyzed by WES and the *SLC25A25* mutation was confirmed by Sanger sequencing. Candidate variant alleles were genotyped in the pedigree using endonuclease restriction analysis.

**2.3 Biochemical Investigations in Southampton 1998: derived values**

Using creatinine clearance as a surrogate for inulin clearance and glomerular filtration rate, and 60% of albumin-corrected serum calcium for ultrafilterable calcium, approximate values for i) *fasting tubular reabsorption of Ca* was estimated from the paired fasting blood and random urine samples: 1-Ca clearance/creatinine clearance x 100% ; [= 1- urine Ca x plasma creatinine /urine creatinine x plasma ultrafilterable Ca x100%], and ii) *percent of Ca reabsorbed over 24h* = Ca reabsorbed/ Ca filtered over 24h x100%, where filtered Ca (mmol/24h) =ultrafilterable Ca x creatinine clearance (L per 24h) and reabsorbed Ca = filtered-24h urine Ca (mmol/24h). To assess tubular phosphate reabsorption, t*he renal threshold phosphate concentration (TmPO4/GFR)* was estimated from paired fasting blood and urine samples using a nomogram (Walker, 2013; Walker 2015).

**2.4 Gene analyses**

**Exome sequencing**

*In Southampton:* Extracted DNA was assessed for quality and analyzed by WES. Library capture was performed using the Agilent SureSelect All Exon V.5 and sequenced using Illumina HiSeq platform. Raw sequence data were analyzed using a local pipeline for sequence alignment to human genome hg19/GRCh 37. To maximize sensitivity, variants for individual samples were called contemporaneously in Samtools v1.3.2 and GATK (v3.6) HaplotypeCaller. The resultant merged VCF files were annotated using ANNOVAR (2015Dec14 release). The sequences were first cross-referenced against a panel of 366 genes relevant to stones which we extracted from published data(Table S1)*.* Variants were then excluded if: they were common (minor allele frequency (MAF) > 0.02 in the 1000 Genome project); present in homopolymer tracts or repeat regions; had read depth <10; were located in highly mutable genes; had a strand-, or base-quality bias and; were not identified in all three stone formers. This analysis was followed by more aggressive filtering of data outside the 366 gene-panel with exclusion of synonymous, non-frameshift insertion or splicing or ncRNA splicing variants, or those with frequency of >2% in the in-house Southampton database of around 600 individual exomes. All remaining variants were then prioritized through multi-disciplinary team discussion according to rarity (EXAC, 1000 Genomes), predicted pathogenicity (SIFT, site conservation (Gerp++, Phylop scores) and likely clinical relevance.

*In Italy:* WES was undertaken by the Centre for Applied Genomics (TCAG; Toronto, Ontario, Canada). Paired end sequencing of DNA fragments (average 200 bp) was carried out using the HiSeq 2500 platform (Illumina Inc., San Diego, CA, USA). Sequence reads were trimmed using Trimmomatic (Bolger et al. 2014) and aligned to the reference human genome sequence (hg19/GRCh 37). Single nucleotide variants and indels were called using GATK haplotype caller v. 3.2.2. (DePristo et al., 2011). Variants were filtered to identify rare polymorphisms using publicly available databases (1,000 Genomes; Exome Aggregation Consortium (ExAC) browser, NHLBI Exome Sequencing Project (ESP) and dbSNP).

**Genotyping**

In Southampton, selected variants were analyzed for segregation across all available family members using Kaspar genotying (KASP TM; LGC, Hoddesdon, Herts, UK). In Italy, the c.1047G>C variant (transcript reference sequence NM\_001006641.3) was confirmed in the proband (II-2) and his son (III-3) by bidirectional Sanger sequencing of the PCR-amplified *SLC25A25* primers 3’-CTGCTCCTGTTGTGCAGGT-5’ (forward; Tm 60 °C) and 3’-TGCTGGGAGGAGGTTTCTAA-5’ (reverse; Tm 59.8 °C). Other family members were genotyped by restriction analysis of the 227-bp PCR amplicon with *Bsr*I or *Rsa*I (New England Biolabs, Ipswich, MA, USA) whose restriction sites are abolished by the c.1047G>C transversion.

**2.5 Computational modelling of APC3b**

Models of the APC3 isoform b, APC3b, were generated in MODELLER (Webb & Sali, 2014), using the bovine mitochondrial **ADP**/ATP carrier (adenine nucleotide translocase) AAC1 (PDB: 1okc) and the fungal ADP/ATP carrier structures (PDB:4c9g, 4c9h, 4c9j, 4c9q) as templates (Pebay-Peyroula et al., 2003, Ruprecht et al., 2014). The structure of the calcium-regulatory domain was taken from PDB:4zcu (Harborne, Ruprecht & Kunji 2015). Models were visualized and the most likely rotamer for the histidine substitution at position 349 was selected in PyMOL Molecular Graphics System, Version 1.8 (Schrödinger LLC, New York, USA).

**2.6 Expression, purification and functional characterization of wild-type and mutant APC3b**

The human wild-type APC3b and the disease variant were expressed in yeast mitochondria, purified, analyzed by thermal stability assays and reconstituted, as described previously (Hofherr et al., 2018). Briefly, purified protein (~60 μg) was reconstituted into liposomes containing L-α-phosphatidylcholine (Avanti Polar Lipids, Alabaster, USA) and tetraoleoyl cardiolipin (Avanti Polar Lipids, Alabaster, USA) in a 20:1 (w/w) ratio. The detergent pentaethylene glycol monodecyl ether was added to a final concentration of 1.6% (v/v) to solubilize the lipids, and the detergent was removed by multiple additions of SM-2 bio-beads (Bio-Rad, Hemel Hempstead, UK) in the presence of 1 mM ATP-Mg. The external substrate was removed using a PD10 desalting column (GE Healthcare, Little Chalfont, UK). Transport rates were determined by measuring the uptake of 2 μM [14C]-ATP with or without the addition of 1 mM CaCl2 over a 15-minute time-course. Uptake curves were fitted with a One-Phase Association model (GraphPad, Prism).

**2.7 Protein analysis**

Proteins were separated using precast 4-12% TruPAGE™ SDS-PAGE gels (Merck KGaA, Darmstadt, Germany), loaded with 5 µg of protein at 3:1 mix of sample to loading buffer and stained using InstantBlue™ Coomassie (Merck KGaA, Darmstadt, Germany). Protein concentration was determined using NanoDrop ND-1000 Spectrophotometer (NanoDropTechnologies) at absorbance at 280 nm.

**2.8 UK Biobank search for the selected rare gene variants**

UK Biobank is a prospective cohort study to investigate risk factors for the major diseases of middle and old age. Between 2006 and 2010 the study recruited around 500,000 men and women aged 40-69 years who have had whole genome genotyping undertaken and allowed linkage of their data with their medical records (Collins, 2012). A genome-wide association study of renal stone disease has recently been undertaken in UK Biobank from 6,536 stone formers (66.7% men) and 388,508 controls (45.5% men) of white British ancestry, mean ages (SD) 67.9 (7.63) years and 66.8 (8.01) years, respectively (Howles, 2019).

We sought to compare the population frequencies of the six variants prioritised from the Southampton WES data (*SLC25A25, VPS16, PLA2R1, MAP3K5, PKP4* and *HAVCR1*) in the 6,536 Biobank stone formers and 388,508 non-stone formers from the GWAS. Genotype data were available for five out of six of these variants (all except the *HAVCR1* variant, which was not present on the UK Biobank Axiom array). Minor allele frequencies were compared for stone formers versus non-stone formers using PLINK, a tool for GWAS and population-based linkage analysis (Purcell, Neale, Todd-Brown, et al., 2007), and a chi-squared test was performed. A Bonferroni correction was applied to account for multiple testing, with the significance threshold set at P<0.01 (0.05/5).

**3 RESULTS**

**3.1 Follow-up of Southampton patients**

From the questionnaire in 2016, no new stone formers were identified in the family and none of the children of generation IV had had stones. From the participants and hospital records, three family members (I-4, II-3, III-5) had had gallstones, one had developed diabetes mellitus, and five had hypertension. None had chronic muscle problems, but on separate courses of two statins for polygenic hyperlipidemia, one participant had muscle pains. There were no results available for creatine kinase during these events. (Table S2).

**3.2 Biochemical assessment in 1998: Southampton family**

The frequent biochemical risk factor identified in 1998 was a decrease in renal phosphate reabsorption, (‘hyperphosphaturia’) in 6 of 12 participants (renal threshold phosphate concentration, TmPO4/GFR < O.80 mmol/L; Table S3). Only one individual (IV-6) had an increased 24h urine calcium excretion, and across the pedigree calcium was reabsorbed well from the kidneys, exceeding 97 % in all but two of the 12 participants (II-6 and IV-6) over 24 hours, and in one (II-6) when fasting. Patient II-6 had an in-dwelling catheter and bladder stone.

**3.3 Identification of a rare variant in *SLC25A25* and other rare variants among the stone formers**

Initial filtering of whole exome variants in Southampton identified two variants that fulfilled all selection criteria. One (rs41288957), in *MAP3K5* (*mitogen activated* *kinase kinase kinase 5, ASK1,* OMIM 602448*)* had predicted low pathogenicity (SIFT 0.36, Polyphen: 0.002). The other (rs140777921) was in *SLC25A25* (dbSNP: chr9: 130868670G>C, (GRCh37.p13). This gene had been included in the candidate gene list because its expression (mRNA) in mouse kidney changed significantly with glyoxylate induced calcium oxalate crystallization (Okada et al., 2009). The second round of filtering identified rare, predicted deleterious, variants in four genes expressed in kidneys, but with no reported association with stones to date: rs61729229 in *VPS16 (vacuolar protein sorting 16 homolog;* OMIM 608550*),* rs201441165 in an isoform of *HAVCR1* (*Hepatitis A Virus Cellular Receptor 1; kidney injury molecule 1, KIM-1;* OMIM 606518); rs15121559 in *PLA2R1 (phospholipase A2 receptor 1*;OMIM 604939), and rs140419507 in *PKP4* (*plakophilin 4, catenin 4*; OMIM 604276). The *VPS16* and *HAVCR1* variants segregated with stone formers and not with non-stone formers while *PLA2R1*, *MAP3K5*, *PKP4*, and *SLC25A25* (Figure 1a; Figure 2) showed incomplete segregation and were initially assigned lower priority.

**Figure 2 Segregation of gene variants & phosphaturia in the Southampton kindred**

Rare variants in six genes identified by WES in stone formers II-1, III-5 and III-7 were selected for their possible relevance to stone formation in this kindred. These variants were then analyzed for segregation across all 12 available family members using Kaspar genotyping (KASP TM; LGC, Hoddesdon, Herts, UK). Orange indicates heterozygosity for the rare allele; green indicates the common allele.

WES screening of II-2 and III-3 in the Italian kindred identified the same rs140777921 variant of *SLC25A25*, which was verified by Sanger sequencing. The variant segregated completely with stone formation (Figure 1b); and occurred in only three of the 12 non-stone formers tested. The *VPS16* variant was not associated with stones in this kindred.

**3.4 Comparisons with data from UK Biobank**

**Table 1 Frequencies of five rare variant alleles from data held on the UK Biobank for DNA from 6,536 stone formers and 388,508 non-stone formers**

Table 1 shows the frequencies of the rare variants of *SLC25A25, VPS16, PLA2R1, MAP3K5* and *PKP4* in the UK Biobank data for UK stone formers and non-stone formers. There were no statistically significant differences that withstood multiple testing correction between the allele frequencies in the two groups, suggesting that these rare variants are not associated with stone disease at the population level.

**3.5 APC3 isoforms: selection of APC3b**

APC3 has four isoforms generated by alternative gene splicing, resulting in proteins with a common C-terminal region but with variations in the N-terminal region. Of these,mRNA forAPC3a is widely expressed, highest in skeletal and heart muscle and pancreas, and moderate in the kidneys. mRNA forAPC3b has a more restricted and lower expression, limited to kidneys, brain and lungs. The amino acid sequences are identical from residue 54 to 469 (APC3a) and 87 to 503 (APC3b), and the main difference is that APC3a has three EF hands in the N-terminal region, whereas APC3b has four (del Arco, 2004; Satrústegui, Pardo & del Arco, 2007). The rs140777921 SNP is a G/C change in the *SLC25A25* gene; Chr 9: 130868670 G>C (GRCh37.P13 build). It is a missense variant which leads to substitution of histidine for glutamine in the transcripts of both the APC3a isoform (p.Gln315His in NM\_052901.4) and the APC3b isoform (p.Gln349 His in NM\_001006641.3).

It also overlaps four other *SLC25A25* transcripts not expressed in the kidneys. It is rare (MAFgnomAD v3.1.1 =0.0018; MAFSouthampton Database = 0.0033), at a highly conserved site (Phylop: 0.999532; Gerp++: 5.08), and predicted to be deleterious by *in-silico* analysis (Combined Annotation Dependent Depletion, CADD v1.6: 26; Rentzsch, Schubach, Shendure, & Kircher, 2021). Three other stone-forming kindreds investigated by WES to date in the Southampton study do not have the variant. We opted to study APC3b because of the renal phenotype of the families and because this transcript was investigated previously in a study of TRPP2, a component of the renal polycystin 2 complex (Hofherr, 2018).

**3.6 Modelling: The p.Gln349His variant could lead to destabilization of the domain structure of APC3b**

APC3 alters the adenine nucleotide pool in the mitochondrial matrix in order to meet increased demand for cellular ATP and energy. It is activated by an increase in cytosolic calcium (Amigo et al., 2013; Aprille, 1993). The transporter has three structural domains; (i) a calmodulin-like N-terminal domain in the mitochondrial intermembrane space, which is involved in calcium regulation, (ii) a loop domain with an amphipathic helix, and (iii) a C-terminal mitochondrial carrier domain with six transmembrane and three matrix helices, which is involved in transport of substrates (Harborne, Ruprecht & Kunji, 2015; Harborne, King, Crichton, & Kunji, 2017). (Figure 3d). In the presence of calcium, the amphipathic helix is bound to the regulatory domain, allowing transport to occur (Harborne, 2015). In the calcium-free state, the amphipathic helix is released, binds to the carrier domain and inhibits transport (Fiermonte, 2004; Harborne, 2017).

**Figure 3 The glutamine to histidine substitution at position 349 in APC3b may compromise an intradomain interaction** (a) Amino acid alignment of human ADP/ATP carrier paralogues 1-4 (AAC1-4), bovine ADP/ATP carrier 1 (AAC1) and ATP-Mg/ Pi carrier paralogues (APC1, APC2, APC3a, APC3b and APC4). The residues participating in the glutamine/glutamate-arginine interaction in the interface between the odd number helix (H3) and the matrix helix (h34) in domain 2 are indicated with green (arginine) and blue (glutamine/ glutamate) diamonds. Lateral view of (b) bovine AAC1 (PDB: 1okc) and (c) APC3b from the membrane in the cytoplasmic-open state, showing the residues described in (a). The regulatory domain (cyan), amphipathic helix (purple), carrier domain (wheat), calcium ions (green spheres) are shown. Enlarged view of intradomain interactions of (d) AAC1 and (e) APC3b wild-type (top) and p.Gln349His (bottom). The arginine (green), glutamine/ glutamate (blue) and the pathogenic variant p.Gln349His (pink), the interactions (grey dash) and distances (Å) are indicated. The tyrosine (green) in APC3b (not present in AAC1) may also contribute to the stabilization of domain 2. The model of APC3b was generated using MODELLER (Webb and Sali, 2014) using the bovine AAC1 (PDB: 1okc) and the yeast ADP/ATP carrier structures (PDB: 4c9g, 4c9h, 4c9j and 4c9q) as a template (Pebay-Peyroula, 2003; Ruprecht, 2014).

The variant is in the carrier domain, and hence could potentially affect the transport function of APC3b. The mutated Gln349 residue is conserved among all ATP-Mg/Pi carriers and is in an equivalent position to a highly conserved glutamate residue in human ADP/ATP carriers (Glu152 in human adenine nucleotide translocase AAC1) (Figure 3a). These residues interact with a positively charged amino acid located two residues down-stream of a highly conserved Px[ED]xx[RK] motif of transmembrane helix 3 (H3) (Miniero et al., 2011; Ruprecht, 2014), Arg139 in AAC1 and Arg341 in APC3b. A glutamine to histidine substitution introduces a bulkier and less flexible side chain (Figure 3e). There are fewer backbone-dependent rotamers for the histidine side chain (3 out of 7) than for the glutamine side chain (8 out of 16), which could interact with Arg341. At the pH of the mitochondrial matrix (~pH 7.8), the imidazole ring of histidine is likely to be partially charged (pKa ~6), and depending on the position of the deprotonated nitrogen, p.Gln349His is either 2.9 Å or 4.6 Å distance from Arg341 (Li & Hong, 2011). The substitution could therefore disrupt the interaction with Arg341 and destabilize the domain. Further, Gln349 precedes [YF]xG, a highly conserved motif at the N-terminus of the matrix helices involved in binding cardiolipin, which is important for mitochondrial carrier function (Klingenberg, 2009; Pebay-Peyroula, 2003; Ruprecht, 2014; Ruprecht et al., 2019) (Figure S1). Disturbance of cardiolipin binding could be another destabilizing factor.

**3.7 The transport activity of the p.Gln349His variant is severely affected**

To determine the effect of the variant on the transport activity, human wild-type and p.Gln349His APC3b were expressed in yeast mitochondria and purified. The protein purity and yield for the p.Gln349His variant were comparable to wild type, indicating that the variant did not impact the expression and targeting of the carrier (Figure S2). Thermal stability assays were used to test whether the p.Gln349His mutation had an effect on the apparent melting temperature (*Tm*), a relative measure of protein stability (Figure 4a). Both wild type and p.Gln349His gave an apparent *Tm* of 45.5 oC (three technical repeats) for the folded form in the presence of calcium. However, the variant displayed a higher baseline, a decreased derivative peak, and a series of folding intermediates at lower melting temperatures, indicative of a partially folded protein population. These observations agree with the notion that the protein itself is active, but that a part of the protein population might be unstable. Uptake assays were performed to assess the effect of the p.Gln349His variant on the transport activity. Purified wild type and p.Gln349His variant were pre-treated with the calcium chelator EGTA (10 mM) in order to minimize free calcium in the sample, before being exchanged into assay buffer.

**Figure 4 Effect of p.Gln349His on the thermal stability and transport activity of APC3b.** (a) Thermostability profile (left), and its corresponding first derivative (right) of APC3b wildtype and p.Gln349His. (b) Schematic representation of proteoliposomes and the conditions tested. (c) A representative uptake curve showing the uptake of [14C]-ATP-Mg into proteoliposomes for APC3b wildtype (left) and pGln349His (right) with (red line) and without (black line) added calcium (1 mM). The error bars represent the standard deviation of four technical replicates. (d) Residual transport activity of APC3b p.Gln349His relative to APC3b wildtype, based on the initial transport rate and corrected for background binding with (red) and without (black) addition of 1mM calcium. The error bars represent the standard deviation of four independent experiments, and the uptake curves are fitted with a one-phase association curve**.**

Wild-type and p.Gln349His APC3b were reconstituted into proteoliposomes and the uptake of radio-labelled ATP was monitored with and without calcium. In the presence of calcium, the uptake assays showed transport activity for both, but the overall activity of the p.Gln349His variant was only 21.6 ± 7% of the wild type (4 independent biological repeats). In the absence of calcium, transport by the p.Gln349His variant was similarly decreased to only 20.4 ± 5.3% residual activity (4 independent biological repeats) (Figure 4). These results indicate that the p.Gln349His variant impacts the specific transport rate of ATP-Mg, without affecting calcium regulation, which could be due to an unfolded subpopulation.

**4 DISCUSSION**

This study found that a rare autosomal dominant inherited missense variant of the gene for APC3, a mitochondrial Mg-ATP transporter, is associated with renal calcium stones with incomplete penetrance. The mutated gene encodes a dysfunctional protein.

APC3 mediates the net import or export of adenine nucleotides in mitochondria. Since it has calcium binding EF-hand motifs facing the extra-mitochondrial space, the activity of the transporter is regulated by cytosolic calcium. Hence APC3 can transduce calcium signals into the mitochondria without requiring calcium entry into the matrix (del Arco, 2004; Fiermonte, 2004). Structural modelling shows that the affected residue in the p.Gln349His variant is positioned in the interface between transmembrane helix 3 (H3) and the matrix helix (h34) interacting with Arg341, which might be important for stability of the transport protein. The transport activity of the p.Gln349His variant was significantly reduced to approximately one fifth of that of APC3b wild type, whereas the calcium regulation was unaffected. Thermostability assays show that a subfraction of the carrier population might be unfolded, which would explain the lower specific activity. The *in vivo* activity of the mutant carrier paired with a wild type allele in the biallelic state, as in the stone patients, cannot be predicted from these experiments. However, heterozygousmissense mutations of the gene for APC1, *SLC25A24,* present with a severe developmental phenotype (Ehmke et al., 2017; Writzl et al., 2017), indicating that mutations of this closely related protein have a dominant negative effect.

To date there are no reports of APC3 deficiency in humans and few reports from experimental animal models. In a study to address the effects of APC3 deficiency on energy metabolic efficiency, mice with global *Slc25a25* deletion were viable at birth, had small decreases in both fat and lean body mass after weaning, reduced exercise endurance and were resistant to diet-induced obesity. The kidneys were not examined and renal function was not investigated. Fibroblasts from *Slc25a25* -/- mouse embryos had decreased mitochondrial respiration and ATP, and decreased flux of Ca2+ across the endoplasmic reticulum (Anunciado-Koza et al., 2011). There was no evidence of abnormally low exercise tolerance in the Southampton family. The statin-induced muscle pain in one individual is of questionable relevance.

The *SLC25A25* disease variant, associated with stones, could impair the ability of the mitochondrion to regulate the production of ATP. Many primary mitochondrial disorders may affect the kidneys, with a wide range of damaging effects. Stones and/or nephrocalcinosis have been reported in patients with mitochondrial depletion, in which dNTP pools may be reduced, in Kearns Sayer Syndrome, and in non-specific multiorgan mitochondrial disorders (Finsterer & Scorza, 2017).

The kidneys have a high energy requirement for transport of minerals and other components of the renal filtrate, with ATP consumption exceeding 2 kg/day (Walker, 2019). ATP depletion is likely to impact significantly on solute reabsorption throughout the nephron and this could lead to production of lithogenic urine. Metabolomic investigation of human *distal* renal tubular cells *in vitro* found that ATP was significantly reduced by *SLC25A25* knock-down, and that concentrations of 42 metabolites changed significantly (Hofherr, 2018). The first tangible evidence for the importance of SLC25A25 as an energy supplier in the kidney *in vivo* is from a study investigating genome-wide gene expression (mRNA) in response to acute and prolonged metabolic acidosis in proximal renal tubular cells from mice. *Slc25a25* was one of the genes with highest increase in expression in both conditions. Oxidative phosphorylation was the most up-regulated cell pathway. It was proposed that in combination these responses supply ATP to fuel membrane transporter processes (Nowik et al., 2008)

Half of the Southampton family members, all with the variant, had hyperphosphaturia. This is common among stone formers, affecting around 30%. The explanation is unknown. Phosphate reabsorption occurs in the proximal tubules and is energy-dependent. In this kindred the rare *SLC25A25* polymorphism might have contributed to hyperphosphaturia. Although hyperphosphaturia alone is unlikely to cause stones, it may do so in the presence of other urine abnormalities. The urinary profiles in 1998 did not include glucose, amino acids or low molecular weight proteins to investigate proximal tubular dysfunction specifically. However, there is tangential evidence that two functions of the proximal tubular functions were not significantly compromised at this time: normal citrate excretion indicates that the intracellular pH of the luminal epithelium was maintained within physiological limits, and excretion of oxalate was normal. This is regulated, in part, by proximal tubular carriers. Calcium was well absorbed and hypercalciuria was not a risk factor for stones in this family. No biochemical data are available for the Italian kindred.

As well as serving as an energy source, ATP is discharged extracellularly throughout the nephron for autocrine/paracrine purinergic signaling when renal cells are stretched by an increase in cell volume due to hypo-osmolarity or to pressure changes in the renal tubules, or are stimulated by high flow rates through the tubular lumen bending cilia on the apical cell membranes. These stimuli trigger calcium release from intracellular stores, and ATP discharge through the plasma membrane, probably via pannexin channels (Burnstock, Evans & Bailey, 2014; Praetorius & Leipziger, 2013). The intracellular source for this burst of ATP for purinergic signaling is unknown. In polymorphonuclear neutrophils, it was shown to be the mitochondria (Bao et al., 2014). Recent studies by Hofherr et al. (Hoffher, 2018) implicate APC3 in the cilia-triggered response to flow. They demonstrated that APC3 is one of the calcium-activated proteins that acts down-stream of the polycystin-2 (TRPP2) ion channel, a component of the polycystin complex in cilia. In addition, knock-down of *Slc25a25* in zebra fish larvae disrupted normal body lateralization, typical of cilia dysfunction. In the distal renal tubules, purinergic stimulation normally protects the body from fluid overload by reducing sodium and water reabsorption, promoting a diuresis of dilute urine (Burnstock, 2014; Praetorius, 2013). A defective purinergic response might increase the concentration of minerals at this site and the risk of crystallization. To date, this possibility has received scant attention. The capacity to dilute urine was not tested in the Southampton family. Bile flow is similarly stimulated by flow and hypotonicity, calcium-induced ATP release and purinergic signaling (Gradilone et al., 2007). It is possible that this response was reduced by the variant, contributing to gallstone formation in this kindred. Gallstone and kidney stone formation are independently associated (Taylor, Chan, Giovannucci & Curhan, 2011). Further studies in an animal model are required to explore the effects of the *SLC25A25* variant *in vivo*.

In the families reported, the *SLC25A25* mutation was clearly not a fully penetrant cause of stone formation, indicating that in isolation it has only a modest effect on the susceptibility to stones. Other gene variants are likely to act as important modifiers to compound the risk, as in other complex polygenic disorders (Pallson, 2019; Pang et al., 2021). Possibilities in the Southampton family are those identified in *VPS16* and *HAVCR1* which code fora cell trafficking protein and the kidney injury molecule, KIM1, respectively, and the three considered less likely because of poor segregation with stones: *PLA2R1*, *MAP3K5* and *PKP4*. Five large cross-sectional population GWAS studies have looked for associations between stones and common gene variants, two from Iceland (Odsson et al., 2015; Thorleifsson et al., 2009), two from Japan (Urabe et al., 2012, Tanikawa, 2019) and one from the UK (Howles, 2019). The majority of the variants detected are non-coding, and functional studies to assess their relevance are lacking. It is notable that only six of the reported genes mapped closely to genes for membrane channels or transporters. The roles of many of the others in renal function or mineral turnover are currently unclear.

The Analysis of data from the UK Biobank data set did not demonstrate a statistically significant association of the *SLC25A25, VPS16*, *PLA2R1*, *MAP3K5* and *PKP4* variantswith stones. This can be explained by lack of statistical power for rare variant detection. Unless the polymorphism has a large effect on phenotype, extremely large study populations are required to demonstrate statistical associations for rare variants. In addition, due to the wide phenotypic heterogeneity of calcium stone disease, inaccurate reporting may have led to misclassification of the Biobank study participants into stone formers/ non-stone formers. This would impact significantly on the size of the small group with the variant, whilst having little effect on the large group with the common allele (Pallson, 2019; Pang et al., 2021).

This is the first report which links stones to a dysfunctional mitochondrial transporter. The exciting feature of this gene is that it is regulated by changes in intracellular calcium which, in turn, mediate cell signaling and ATP release. APC3 may be a key intermediary for adapting mitochondrial activity to molecular transport at the cell surface. Applied selectively to families or cohorts of individuals with a clearly defined clinical and biochemical phenotype, WES has great capability to identify rare variants that contribute to stone risk which could not be predicted from our current limited understanding. It is essential that novel, unexpected associations, are explored by functional studies. Data and experience must be shared to progress our understanding of recurrent stone formation and prevention strategies.

**ACKNOWLEDGEMENTS**

The authors thank Prof. Lesley Foulkes and Dr. Damian Griffin for their work with the Southampton family in 1998, Nicki Graham for assistance with DNA preparation and transport, Dr. Paul Cook for help with patient recruitment, Dr. Shane Palmer for the fermenters runs required to obtain material for the functional studies, and the families for their collaboration.

**CONFLICT OF INTEREST**

M.R Jabalameli, F. Fitzpatrick, R. Colombo, S.A. Howles, E.R.S. Kunji, G. P. Leggatt, V. Walker, A. Wiberg and S. Ennis, declare that they have no conflict of interest

**AUTHORS’ CONTRIBUTIONS**

MRJ, GL and SE undertook and interpreted the genomic studies in Southampton. RC investigated the Italian pedigree and co-ordinated genomic studies in his laboratory. ERSK undertook computational modelling of SLC25A25 and the disease variant, and FF and ERSK carried out the functional studies. SH co-ordinated the Biobank study and SH and AK analysed the Biobank data. VW conceived and co-ordinated the Southampton study and drafted the manuscript. All Authors contributed to the final manuscript.

**DATA AVAILABILITY STATEMENT**

The data that supports the findings of this study are available in the supplementary material of this article.

**Submission to ClinVar:** submission by Reza Jabalameli acknowledged on 01 July 2020 and is being processed; Submission ID: SUB7695666; Organization ID: 505638

**SUPPORTING INFORMATION:**

**Supplementary Tables: Tables SI, S2, S3**

**Supplementary Document: Document S1**

**Supplementary Figures: Figures S1, S2**

**REFERENCES**

Amigo, I., Traba, J., González-Barroso, M.M., Rueda, C.B., Fernández, M., Rial, E.---del Arco, A*.* (2013)*.* Glucagon regulation of oxidative phosphorylation requires an increase in matrix adenine nucleotide content through Ca2+ activation of the mitochondrial ATP-Mg/Pi carrier SCaMC-3. *Journal of Biological Chemistry, 288.* 7791–7802. https://doi. 10.1074/jbc.M112.409144

Anunciado-Koza, R.P., Zhang, J., Ukropek,J., Bajpeyi,S., Koza,R.A., Rogers, R.C.----Kozak, L.P. (2011). Inactivation of the mitochondrial carrier SLC25A25 (ATP-Mg2+/Pi transporter) reduces physical endurance and metabolic efficiency in mice. *Journal of Biological Chemistry*, *286.* 11659-11671. https://doi. 10.1074/jbc.M110.203000

Aprille, J.R. (1993). Mechanism and regulation of the mitochondrial ATP-Mg/P(i) carrier. *Journal of Bioenergetics and Biomembranes*,*25.* 473–481. https://doi.10.1007/BF01108404

Bao, Y., Ledderose, C., Seier, T., Graf, A.F., Brix, B., Chong, E., Junger, W.G. (2014).

signaling. *Journal of Biological Chemistry*, *289*. 26794-26803. https://doi. [10.1074/jbc.M114.572495](https://dx.doi.org/10.1074%2Fjbc.M114.572495)

Bolger, A.M., Lohse, M., Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*, *30*. 2114-2120. https://doi. 10.1093/bioinformatics/btu170

Braun, D.A., Lawson, J.A., Gee, H.Y,--- Hildebrandt, F. (2016). Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. *Clinical Journal of American Society of Nephrology,* *11*. 664-672. https://doi.org/10.2215/CJN.07540715

Burnstock, G., Evans, L.C., Bailey, M.A. (2014). Purinergic signalling in the kidney in health and disease. *Purinergic Signalling, 10*. 71-101. https://doi.[10.1007/s11302-013-9400-5](https://dx.doi.org/10.1007%2Fs11302-013-9400-5)

Coe, F.L., Evan, A., Worcester, E. (2005). Kidney stone disease. *The Journal of Clinical Investigation*, *115.*2598-2608. https://doi.10.1172/JCI26662

Collins, R. What makes UK Biobank special? (2012). *The Lancet, 379*. 1173-1174. https://doi.10.1016/S0140-6736(12)60404-8.

* Curhan, G.C., Willett W.C., Rimm, E.B., Stampfer, M., J. (1997). Family history and risk of kidney stones. *Journal of the American Society of Nephrology, 8.* 1568-1573. https://doi [10.1681/ASN.V8101568](https://doi.org/10.1681/asn.v8101568)

Daga, A., Majmundar A.J., Braun D.A., --- Hildebrandt, F. (2018). Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. *Kidney International*, *93.* 204-213. https://doi.10.1016/j.kint.2017.06.025

del Arco A., & Satrústegui J. (2004). Identification of a novel human subfamily of mitochondrial carriers with calcium-binding domains. *Journal of Biological Chemistry, 279.* 24701-24713. https;//doi.10.1074/jbc.M401417200

DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C.----- Daly,

M.J. (2011). A framework for variation discovery and genotyping using next-generation DNA

sequencing data. *Nature Genetics*, *43*.491-498. https://doi. 10.1038/ng.806.

Ehmke, N., Graul-Neumann, L., Smorag, L., Koenig, R., Segebrecht, L., Magoulos, P.----

Kornak, U. (2017). *De Novo* Mutations in *SLC25A24* cause a craniosynostosis syndrome with

hypertrichosis, progeroid appearance, and mitochondrial dysfunction. *American Journal of*

*Human Genetics,* *101*. 833–843. https:// doi.10.1016/j.ajhg.2017.09.016

Fiermonte, G., de Leonardis, F., Todisco, S., Palmieri, L., Lasorsa, F.M., Palmieri, F. (2004) Identification of the mitochondrial ATP-Mg/Pi transporter. Bacterial expression, reconstitution, functional characterization and tissue distribution. *Journal of Biological Chemistry*, *279*. 30722-30730. https://doi.10.1074/jbc.M400445200

Finsterer, J., & Scorza, F. (2017). Renal manifestations of primary mitochondrial disorders (Review). *Biomedical Reports, 6*. 487-494. https://doi. 10.3892/br.2017.892.

Gambaro, G., Croppi, E., Coe, F., Lingeman, J., Moe, O., Worcester, E. *----*& The Consensus Conference Group. (2016). Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. *Journal of Nephrology*, *29*. 715-734. https://doi. [10.1007/s40620-016-0329-y](https://dx.doi.org/10.1007%2Fs40620-016-0329-y)

Goldfarb, D.S., Avery A.R., Beara-Lasic, L., Duncan, G.E., Goldberg, J. (2019). A twin study of genetic influences on nephrolithiasis in women and men. *Kidney International Reports*, 4. 535-540. https://doi.[10.1016/j.ekir.2018.11.017](https://dx.doi.org/10.1016%2Fj.ekir.2018.11.017)

Gradilone, S.A., Masyuk, A.I., Splinter, P.L., ----LaRusso, N.F. (2007). Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. *Proceedings of the National Academy of Sciences USA, 104*. 19138-19143. https://doi. [10.1073/pnas.0705964104](https://dx.doi.org/10.1073%2Fpnas.0705964104)

Halbritter, J., Baum, M., Hynes, A.M., --- Hildebrandt F. (2015). Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. *Journal of the American Society of Nephrology 26*. 543-551. https://doi.10.1681/ASN.2014040388

Harborne, S.P.D., King, M.S., Crichton, P.G., Kunji, E.R.S. (2017). Calcium regulation of the human mitochondrial ATP/Mg/Pi carrier SLC25A24 uses a locking pin mechanism. *Scientific* *Reports*, *7.* 45383. https://doi. 10.1038/srep45383

Harborne, S.P., Ruprecht, J.J., Kunji, E.R. (2015). Calcium-induced conformational changes in the regulatory domain of the human mitochondrial ATP-Mg/Pi carrier. *Biochimica et Biophysica Acta*, *1847*. 1245–1253. https://doi.org/10.1016/j.bbabio.2015.07.002

Hofherr, A., Seger, C., Fitzpatrick, F., Busch,T., Michel, E., Luan, J.*----*Köttgen, M. (2018). The mitochondrial transporter SLC25A25 links ciliary TRPP2 signaling and cellular metabolism. *PLoS Biology*, *16.* e2005651. https://doi.org/10.1371/journal.pbio.2005651

Howles, S.A., & Thakker, R.V. (2020). Genetics of kidney stone disease. *Nature Reviews Urology* https://doi.org/10.1038/s41585-020-0332-x

Howles, S.A., Wiberg, A., Goldsworthy, M.----Furniss, D. (2019). Genetic variants of calcium and vitamin D metabolism in kidney stone disease. *Nature Communications, 10.* 5175 . https://doi.org/10.1038/s41467-019-13145-x

Klingenberg, M. (2009). Cardiolipin and mitochondrial carriers. *Biochimica et Biophysica Acta,**1788*. 2048–2058. https://doi.org/10.1016/j.bbamem.2009.06.007

Li, S. and Hong, M. (2011). Protonation, tautomerization, and rotameric structure of histidine: a comprehensive study by magic-angle-spinning solid-state NMR. *Journal of the American Chemical Society*, *133*. 1534–1544. https://doi.10.1021/ja108943n.

Miniero, D.V., Cappello, A.R., Curcio, R., Ludovico, A., Daddabbo, L., Stipani, I.----Palmieri, F. (2011). Functional and structural role of amino acid residues in the matrix alpha-helices, termini and cytosolic loops of the bovine mitochondrial oxoglutarate carrier. *Biochimica et Biophysica Acta*, *1807*. 302–310. doi.10.1016/j.bbabio.2010.12.005

Moe 0., W. ( 2006). Kidney stones: pathophysiology and medical management. *The Lancet, 367.* 333-344. https://doi. 10.1016/S0140-6736(06)68071-9.

Nowik, M., Lecca, M.R., Velic, A., Rehrauer, H., Brändli, A.W., Wagner, C.A.(2008) Genome-wide gene expression profiling reveals renal genes regulated during metabolic acidosis. *Physiological Genomics 32:* 322-334. https://doi.org: 10.1152/physiolgenomics.00160.2007

Oddsson, A., Sulem, P., Helgason, H., Edvardsson, V.O., Thorleifsson, G., Sveinbjörnsson, G. ---- Stefansson, K. (2015). Common and rare variants associated with kidney stones and biochemical traits. *Nature Commununications, 6.* 7975. https://doi. 10.1038/ncommuns8975

Okada, A., Yasui, T., Hamamoto, S., Hirose, M., Kubota, Y., Itoh, Y.----Kohri, K. (2009). Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity. *Journal of Bone and Mineral Research, 24*. 908-924. <https://doi.org/10.1359/jbmr.081245>

Palsson, R., Indridason, O.S., Edvardsson, V.O., Oddsson, A. (2019). Genetics of common complex kidney stone disease: insights from genome-wide association studies. *Urolithiasis*, *47.* 11-21.htpps://doi. 10.1007/s00240-018-1094-2

Pang, H., Xia, Y., Luo, S., Huang, G., Li, X., Xie, Z., Zhou, Z. (2021). Emerging roles of rare and low-frequency genetic variants in type 1 diabetes mellitus. *Journal of Medical Genetics,58.*289-296.https:// [doi. 10.1136/jmedgenet-2020-107350](http://dx.doi.org/10.1136/jmedgenet-2020-107350)

Pebay-Peyroula, E., Dahout-Gonzalez, C., Kahn, R., Trézéguet, V., Lauquin, G.J., Brandolin, G. (2003). Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. *Nature, 426.* 39–44. htpps://doi. 10.1038/nature02056

Praetorius, H.A., Leipziger, J. (2013). Primary cilium-dependent sensing of urinary flow and paracrine purinergic signaling. *Seminars in Cell & Developmental Biology, 24.* 3-10. https://doi.org/ [10.1016/j.semcdb.2012.10.003](https://www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org%2F10.1016%2Fj.semcdb.2012.10.003)

Prochaska, M.L., Taylor, E.N., Curhan, G.C. (2016). Insights into nephrolithiasis from the Nurses' Health Studies. *American Journal of Public Health, 106.* 1638-1643. https://doi. 10.2105/AJPH.2016.303319

Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D.---- Sham, P.C. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *The American Journal of Human Genetics, 81.* 559-575. https://doi: [10.1086/519795](https://dx.doi.org/10.1086%2F519795)

Rentzsch, P., Schubach, M., Shendure, J., Kircher, M. (2021). CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores. *Genome Medicine*, *13*. 31. https://doi.[10.1186/s13073-021-00835-9](https://doi.org/10.1186/s13073-021-00835-9).

Ruprecht, J.J., Hellawell, A.M., Harding, M., Crichton, P.G., McCoy. A.J., Kunji, E.R.S. (2014). Structures of yeast mitochondrial ADP/ATP carriers support a domain-based alternating-access transport mechanism. *Proceedings of the National Academy of Sciences USA, 111.* E426-E434. https://doi.[10.1073/pnas.1320692111](https://dx.doi.org/10.1073%2Fpnas.1320692111)

Ruprecht, J.J., King, M.S., Zögg, T., Aleksandrova, A.A., Pardon, E., Crichton, P.G., ----Kunji, E.R.S.(2019). The molecular mechanism of transport by the mitochondrial ADP/ATP carrier. *Cell*, *176.* 435-447. doi.10.1016/j.cell.2018.11.025

Satrústegui J., Pardo B, del Arco A. (2007). Mitochondrial transporters as novel targets for intracellular calcium signaling. *Physiological Reviews, 87*. 29-67. https://doi.org/[10.1152/physrev.00005.2006](https://doi.org/10.1152/physrev.00005.2006)

Sayer JA. (2017). Progress in understanding the genetics of calcium-containing nephrolithiasis. *Journal of the* *American Society of Nephrology,* 28. 748-759. htpps://doi. 10.1681/ASN.2016050576

Tanikawa, C., Kamatani, Y., Terao, C., Usami, M., Takahashi, A., Momozawa, Y.,----- Matsuda K. (2019). Novel risk loci identified in a genome-wide association study of urolithiasis in a Japanese population. *Journal of the American Society of Nephrology, 30.* 855-864 https://doi.org/10.1681/ASN.2018090942

Taylor, E.N., Chan, A.T., Giovannucci, E.L., Curhan, G.C. (2011). Cholelithiasis and risk of nephrolithiasis. *Journal of Urology, 186.* 1882-1887. https:// doi: 10.1016/j.juro.2011.06.067.

Thorleifsson. G., Holm, H., Edvardsson, V., Walters, G.B., Styrkarsdottir, U., Gudbjartsson, D.F.,----Stefansson K. (2009). Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. *Nature Genetics, 41*. 926-930. https://doi. 10.1038/ng.404.

Traba, J., Satrústegui, J., del Arco, A. (2009). Characterization of SCaMC-3-like/slc25a41, a novel calcium-independent mitochondrial ATP-Mg/Pi carrier. *Biochemical Journal,* 418. 125–133. https://doi. 10.1042/BJ20081262

Urabe, Y., Tanikawa, C., Takahashi, A., Okada, Y., Morizono, T., Tsunoda, T.,---- Matsuda, K. (2012). A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible loci at 5q35.3, 7p14.3, and 13q14.1. *PLoS Genetics, 8.* e1002541. https://doi.10.1371/journal.pgen.1002541

Vezzoli, G.,Terranegra, A., Arcidiacono, T., Soldati, L. (2011). Genetics and calcium nephrolithiasis. *Kidney International*, *80.* 587–593. https://doi.10.1038/ki.2010.430

Walker V. (2019). Phosphaturia in kidney stone formers: still an enigma. *Advances in Clinical Chemistry*, *90.* 133-196. https://doi.org/10.1016/bs.acc.2019.01.004

Walker, V., & Griffin, D.G. (2015). Renal calcium and urate handling and diet in idiopathic stone formers. In M. Schneider (Ed). *Neprolithiasis: Risk factors, treatment and prevention* (pp. 67-103). New York: Nova Biomedical. ISBN: 978-1-63482-134-6

Walker, V., Stansbridge, E.M., Griffin, D.G. (2013). Demography and biochemistry of 2800 patients from a renal stones clinic. *Annals of Clinical Biochemistr*y, *50.* 127-139. [https://doi.org/10.1258/acb.2012.012122](https://doi.org/10.1258%2Facb.2012.012122)

Webb, B. & Sali, A. (2014) Comparative Protein Structure Modeling Using MODELLER. *Current Protocols in Bioinformatics*, 47(1). pp. 5.6.1-5.6.32. https://doi.org/10.1002/0471250953.bi0506s47.

Writzl, K., Maver, A., Kovačič, L., Martinez-Valero, P., Contreras, L., Satrustegui, J. *----*Hennekam, R.C. (2017). De Novo Mutations in *SLC25A24* cause a disorder characterized by early aging, bone dysplasia, characteristic face, and early demise. *The American Journal of Human Genetics, 101.* 844–855. <https://doi.org/10.1016/j.ajhg.2017.09.017>